- Home
- STTK vs XBP Comparison
STTK vs XBP Comparison
Compare STTK & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- XBP
- Stock Information
- Founded
- STTK 2016
- XBP N/A
- Country
- STTK United States
- XBP United Kingdom
- Employees
- STTK N/A
- XBP N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- XBP Business Services
- Sector
- STTK Health Care
- XBP Consumer Discretionary
- Exchange
- STTK Nasdaq
- XBP Nasdaq
- Market Cap
- STTK 37.6M
- XBP 32.2M
- IPO Year
- STTK 2020
- XBP N/A
- Fundamental
- Price
- STTK $0.83
- XBP $0.90
- Analyst Decision
- STTK Hold
- XBP
- Analyst Count
- STTK 4
- XBP 0
- Target Price
- STTK $3.00
- XBP N/A
- AVG Volume (30 Days)
- STTK 401.8K
- XBP 94.0K
- Earning Date
- STTK 07-31-2025
- XBP 08-11-2025
- Dividend Yield
- STTK N/A
- XBP N/A
- EPS Growth
- STTK N/A
- XBP N/A
- EPS
- STTK N/A
- XBP N/A
- Revenue
- STTK $4,606,000.00
- XBP $142,332,000.00
- Revenue This Year
- STTK N/A
- XBP N/A
- Revenue Next Year
- STTK N/A
- XBP N/A
- P/E Ratio
- STTK N/A
- XBP N/A
- Revenue Growth
- STTK 69.65
- XBP N/A
- 52 Week Low
- STTK $0.69
- XBP $0.79
- 52 Week High
- STTK $4.99
- XBP $1.89
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- XBP 39.68
- Support Level
- STTK $0.77
- XBP $0.84
- Resistance Level
- STTK $0.91
- XBP $0.93
- Average True Range (ATR)
- STTK 0.08
- XBP 0.08
- MACD
- STTK -0.02
- XBP -0.00
- Stochastic Oscillator
- STTK 16.23
- XBP 22.11
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About XBP XBP Europe Holdings Inc.
XBP Europe Holdings Inc is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and operations partner for its clients' strategic journeys and streamlining their complex, disconnected payment processes. It has two segments Bills and Payments focusing on optimizing how bills and payments are processed by businesses of all sizes and industries and Technology, focuses on sales of recurring and perpetual software licenses and related maintenance, hardware solutions, and related maintenance and professional services. It generates the majority of its revenue from the Bills and Payments segment.